The neurobiology of antiepileptic drugs

Nature Reviews Neuroscience

Volumn 5, Issue 7, 2004, Pages 553-564

  Rogawski, Michael A ^a   Löscher, Wolfgang ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MEPHENYTOIN; MESUXIMIDE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROPOFOL; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; TRIMETHADIONE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ACTION POTENTIAL; CHANNEL GATING; DRUG MECHANISM; DRUG TARGETING; EPILEPSY; EPILEPTIC STATE; GENE MUTATION; HUMAN; NERVE CELL EXCITABILITY; NERVOUS SYSTEM FUNCTION; NEUROBIOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEIZURE;

EID: 3042798891     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1430     Document Type: Review

References (144)

1. Rogawski, M. A. & Löscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature Med. (in the press). A review of the actions of AEDs in conditions other than epilepsy, focusing on disease-related ion channel plasticity and long-term effects on signalling pathways.
2. Tatulian, L., Delmas, P., Abogadie, F. C. & Brown, D. A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 21, 5535-5545 (2001).
3. Rogawski, M. A. in Neurotherautics: Emerging Strategies (eds Pullan, L. & Patel, J.) 193-273 (Humana, Totowa, New Jersey, 1996).
4. Schmutz, M., Brugger, F., Gentsch, C., McLean, M. J. & Olpe, H. R. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35 (Suppl. 5), S47-50 (1994).
5. Ambrósio, A. F. et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem. Pharmacol. 61, 1271-1275 (2001).
6. Schauf, C. L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 413, 185-188 (1987).
7. + channels from human and rat brain. Eur. J. Pharmacol. 316, 373-377 (1996).
8. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 288, 960-968 (1999).
9. Van den Berg, R. J., Kok, P. & Voskuyl, R. A. Valproate and sodium currents in cultured hippocampal neurons. Exp. Brain. Res. 93, 279-287 (1993).
10. Albus, H. & Williamson, R. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia 39, 124-139 (1998).
11. + current in neocortical neurons. Epilepsy Res. 32, 304-308 (1998).
12. + channel expressed in a stable mammalian cell line. Pflugers Arch. 441, 425-433 (2001). In this paper, studies using human brain type IIA voltage-gated sodium channels stably expressed in CHO cells showed voltage- and use-dependent block by phenytoin and lamotrigine, but not valproate and gabapentin.
13. + channels in hippocampal neurons of control and chronically epileptic rats. Eur. J. Neurosci. 17, 2648-2658 (2003).
14. Willow, M., Gonoi, T. & Catterall, W. A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 27, 549-558 (1985).
15. Matsuki, N., Quandt, F. N., Ten Eick, R. E. & Yeh, J. Z. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J. Pharmacol. Exp. Ther. 228, 523-530 (1984).
16. + channels, expressed in mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol. 40, 756-765 (1991). Characterization of the actions of phenytoin and carbamazepine on recombinant rat brain sodium channels.
17. + channels in rat hippocampal neurones. Pflügers Arch. 430, 437-446 (1995).
18. Leach, M. J., Marden, C. M. & Miller, A. A. Pharmacological studies on lamotrigine, a novel potential antiepileptc drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27, 490-497 (1986).
19. Prakriya, M. & Mennerick, S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 26, 671-682 (2000).
20. Goldin, A. L. Mechanisms of sodium channel inactivation. Curr. Opin. Neurobiol. 13, 284-290 (2003).
21. + current and slow cumulative spike adaptation in mouse and guinea-pig neocortical neurones in slices. J. Physiol. (Lond.) 493, 83-97 (1996).
22. Quandt, F. N. Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells. Mol. Pharmacol. 34, 557-565 (1988). Analysis of phenytoin block of single sodium channels in membrane patches.
23. + channels must deactivate to recover from inactivation. Neuron 12, 819-829 (1994). A demonstration that phenytoin stabilizes sodium channels of hippocampal neurons in a nonconducting state, distinct from fast inactivation, from which recovery is slow and requires the channel to deactivate.
24. Spampanato, J., Escayg, A., Meisler, M. H. & Goldin, A. L. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J. Neurosci. 21, 7481-7490 (2001).
25. Alekov, A. K., Rahman, M. M., Mitrovic, N., Lehmann-Hom, F. & Lerche, H. Enhanced inactivation and acceleration of activation of the sodium channel associated with epilepsy in man. Eur. J. Neurosci. 13, 2171-2176 (2001).
26. Spampanato, J., Aradi, I., Soltesz, I. & Goldin, A. L. Increased neuronal firing in computer simulations of sodium channel mutations that cause generalized epilepsy with febrile seizures plus. J. Neurophysiol. 91, 2040-2050 (2004).
27. Vallarta, J. M., Bell, D. B. & Reichert, A. Progressive encephalopathy due to chronic hydantoin intoxication. Am. J. Dis. Child. 128, 27-34 (1974).
28. Löscher, W., Cramer, S. & Ebert, U. Limbic epileptogenesis alters the anticonvulsant efficacy of phenytoin in Sprague-Dawley rats. Epilepsy Res. 31, 175-186 (1998).
29. Kuo, C. C. & Bean, B. P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol. Pharmacol. 46, 716-725 (1994). Phenytoin is found to bind tightly to the fast inactivated state of sodium channels but binding occurs slowly, a key characteristic enabling phenytoin to disrupt epileptic discharges with minimal effects on normal firing activity.
30. + channels in rat hippocampal neurones. Br. J. Pharmacol. 121, 1231-1238 (1997).
31. Bazil, C. W. & Pedley, T. A. In Antiepileptic Drugs, 5th Edition (eds Levy, R. H., Mattson, R. H., Meldrum, B. S. & Perucca, E.) 22-35 (Lippincott Williams & Wilkins, Philadelphia, 2002).
32. + channels. Mol. Pharmacol. 54, 712-721 (1998). Studies with mixtures of the main sodium channel-blocking anticonvulsants demonstrate that these drugs bind to a similar recognition site on the inactivated conformation of the channel.
33. + channels. Proc. Natl Acad. Sci. USA 93, 9270-9275 (1996). Mutational analysis demonstrates the importance of F1764 and Y1771 in sodium channel transmembrane segment IVS6 in the binding of lidocaine and phenytoin.
34. Liu, G. et al. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 44, 413-422 (2003). Site-directed mutagenesis reveals residues of the IVS6 transmembrane segment of the sodium channel that represent points of interaction for lamotrigine.
35. + channel α-subunit. J. Biol. Chem. 276, 20-27 (2001). Site-directed mutagenesis reveals residues of the IIIS6 transmembrane segment of the sodium channel that represent points of interaction for lamotrigine and the local anesthetic etidocaine.
36. McPhee, J. C., Ragsdale, D. S., Scheuer, T. & Catterall, W. A. A critical role for transmembrane segment IVS6 of the sodium channel α-subunit in fast inactivation. J. Biol. Chem. 270, 12025-12034 (1995).
37. Smith, M. R., Smith, R. D., Plummer, N. W., Meisler, M. H. & Goldin, A. L. Functional analysis of the mouse Scn8a sodium channel. J. Neurosci. 18, 6093-6102 (1998).
38. Taddese, A. & Bean, B. P. Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 33, 587-600 (2002).
39. Maurice, N., Tkatch, T., Meisler, M., Sprunger, L. K. & Surmeier, D. J. D1/D5 dopamine receptor activation differently modulates rapidly inactivating and persistent sodium currents in prefrontal cortex pyramidal neurons. J. Neurosci. 21, 2268-2277 (2001).
40. Segal, M. M. & Douglas, A. F. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J. Neurophysiol. 77, 3021-3034 (1977). This paper shows that the tetrodotoxin-sensitive, persistent sodium current that results from rare late openings of voltage-gated sodium channels is more sensitive to phenytoin than is the transient current. Such late openings are hypothesized to be important in initiating and continuing epileptiform activity.
41. + current of mammalian CNS neurones. Neuroreport 6, 1778-1780 (1995).
42. + current. J. Pharmacol. Exp. Ther. 284, 228-237 (1998).
43. Niespodziany, I., Klitgaard, H. & Georg Margineanu, D. Is the persistent sodium current a specific target of anti-absence drugs? Neuroreport 15, 1049-1052 (2004).
44. Ketelaars, S. O., Gorter, J. A., van Vliet, E. A., Lopes da Silva, F. H. & Wadman, W. J. Sodium currents in isolated rat CA1 pyramidal and dentate granule neurones in the post-status epilepticus model of epilepsy. Neuroscience 105, 109-120 (2001).
45. + channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 119, 323-333 (2003).
46. Agrawal, N., Alonso, A. & Ragsdale, D. S. Increased persistent sodium currents in rat entorhinal cortex layer V neurons in a post-status epilepticus model of temporal lobe epilepsy. Epilepsia 44, 1601-1604 (2003).
47. Gastaldi, M., Robaglia-Schlupp, A., Massacrier, A., Planells, R. & Cau, P. mRNA coding for voltage-gated sodium channel β2 subunit in rat central nervous system: cellular distribution and changes following kainate-induced seizures. Neurosci. Lett. 249, 53-56 (1998).
48. Lossin, C., Wang, D. W., Rhodes, T. H., Vanoye, C. G. & George, A. L. Jr. Molecular basis of an inherited epilepsy. Neuron 34, 877-884 (2002). Recombinant human voltage-gated sodium channel SCN1A was coexpressed in cultured mammalian cells with human accessory subunits β1 and β2. GEFS+ mutations T875M, W1204R and R1648H in SCN1A were found to alter channel inactivation, resulting in persistent inward sodium current. This gain-of-function abnormality is hypothesized to represent the biophysical mechanism that is responsible for the epileptic phenotype.
49. 2+ channels. Annu. Rev. Cell Dev. Biol. 16, 521-555 (2000).
50. Tumer, T. J. Calcium channels coupled to glutamate release. Prog. Brain. Res. 116, 3-14 (1998).
51. 3H]gabapentin with high affinity is solubilized and purified; the partial N-terminal amino-acid sequence is identical to the calcium channel α2δ-subunit.
52. 2δ subunits - structure and gabapentin binding. Mol. Pharmacol. 59, 1243-1248 (2001).
53. Bryans, J. S. et al. Identification of novel ligands for the gabapentin binding site on the α2δ subunit of a calcium channel and their evaluation as anticonvulsant agents. J. Med. Chem. 4, 1838-1845 (1998).
54. 3H]- norepinephrine release from rat neocortical slices. Synapse 45, 171-190 (2002).
55. Dolphin, A. C. et al. The effect of α2δ and other accessory subunits on expression and properties of the calcium channel α1G. J. Physiol. (Lond.) 519, 35-45 (1999).
56. Arikkath, J. & Campbell, K. P. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr. Opin. Neurobiol. 13, 298-307 (2003).
57. Brown, J. P. & Gee, N. S. Cloning and deletion mutagenesis of the α2δ calcium channel subunit from porcine cerebral cortex. J. Biol. Chem. 273, 25458-25465 (1998).
58. Wang, M., Offord, J., Oxender, D. L. & Su, T.-Z. Structural requirement of the calcium channel subunit α2δ for gabapentin binding. Biochem. J. 342, 313-320 (1999).
59. 2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropharmacology 42, 353-366 (2002).
60. Sutton, K. G., Martin, D. J., Pinnock, R. D., Lee, K. & Scott, R. H. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Brit. J. Pharmacol. 135, 257-265 (2002).
61. Sarantopoulos, C., McCallum, B., Kwok, W. M. & Hogan, Q. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg. Anesth. Pain. Med. 27, 47-57 (2002).
62. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280, 107-110 (2000).
63. Shimoyama, M., Shimoyama, N. & Hori, Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85, 405-414 (2000).
64. Löscher, W., Honack, D. & Taylor, C. P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci. Lett. 128, 150-154 (1991).
65. Petroff, O. A., Hyder, F., Rothman, D. L. & Mattson, R. H. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 41, 675-680 (2000).
66. Errante, L. D., Williamson, A., Spencer, D. D. & Petroff, O. A. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res. 49, 203-210 (2002).
67. - current. J. Neurosci. 13, 3211-3221 (1993).
68. 2+ currents in cortical neurons: functional implications. Eur. J. Pharmacol. 307, 113-116 (1996).
69. Wang, S.-J., Huang, C.-C., Hsu, K.-S., Tsai, J.-J. & Gean, P.-W. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7, 3037-3040 (1996).
70. 2+ currents. Seizure 10, 279-286 (2001).
71. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. 306, 5-8 (2001).
72. Lukyanetz, E. A., Shkryl, V. M. & Kostyuk, P. G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43, 9-18 (2002).
73. Perez-Reyes, E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. 83, 117-161 (2003).
74. Huguenard, J. R. Low-threshold calcium currents in central nervous system neurons. Annu. Rev. Physiol. 58, 329-358 (1996).
75. Suzuki, S. & Rogawski, M. A. T-type calcium channels mediate the transition between tonic and phasic firing in thalamic neurons. Proc. Natl Acad. Sci. USA 86, 7228-7232 (1989).
76. Talley, E. M. et al. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J. Neurosci. 19, 1895-1911 (1999).
77. 2+ channels. Neuron 31, 35-45 (2001).
78. Tsakiridou, E., Bertollini, L., de Curtis, M., Avanzini, G. & Pape, H. C. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. J. Neurosci. 15, 3110-3117 (1995).
79. Talley, E. M., Solorzano, G., Depaulis, A., Perez-Reyes, E. & Bayliss, D. A. Low-voltage-activated calcium channel subunit expression in a genetic model of absence epilepsy in the rat. Brain Res. Mol. Brain Res. 75, 159-165 (2000).
80. Chen, Y. et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann. Neurol. 54, 239-243 (2003).
81. v3.2 T-type calcium channel associated with childhood absence epilepsy. J. Biol. Chem. 279, 9881-9684 (2004).
82. Heron, S. E. et al. Genetic variation of CACNA1H in idiopathic generalized epilepsy. Ann. Neurol. 55, 595-596 (2004).
83. Coulter, D. A., Huguenard, J. R. & Prince, D. A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic relay neurons. Ann. Neurol. 25, 582-593 (1989). The inhibitory effect of ethosuximide on T-type calcium channels is hypothesized to account for its anti-absence activity.
84. Gomora, J. C., Daud, A. N., Weiergräber, M. & Perez-Reyes, E. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol. Pharmacol. 60, 1121-1132 (2001).
85. McLean, M. J. & Macdonald, R. L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237, 1001-1011 (1986).
86. Leresche, N. et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J. Neurosci. 16, 4842-4853 (1998).
87. Manning, J. P., Richards, D. A., Leresche, N., Crunelli, V. & Bowery, N. G. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience 123, 5-9 (2004).
88. Kito, M., Maehara, M. & Watanabe, K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5, 115-119 (1996).
89. Galarreta, M. & Hestrin, S. Frequency-dependent synaptic depression and the balance of excitation and inhibition in the neocortex. Nature Neurosci. 1, 587-594 (1998).
90. Miles, R. & Wong, R. K. Inhibitory control of local excitatory circuits in the guinea-pig hippocampus. J. Physiol. (Lond) 388, 611-629 (1987).
91. A receptor subunits as a genetic basis of epilepsy.
92. A receptor dysfunction in epilepsy: a mutation in the γ2-subunit gene. Nature Genet. 28, 46-48 (2001).
93. Kananura, C. et al. A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions. Arch. Neurol. 59, 1137-1141 (2002).
94. A-receptor γ2 subunit in a family with generalized epilepsy with febrile seizures plus. Am. J. Hum. Genet. 70, 530-536 (2002).
95. A receptor mutations linked to epilepsy in humans. J. Neurosci. 22, 5321-5327 (2002).
96. Cossette, P. et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nature Genet. 31, 184-189 (2002).
97. Gallagher, J. P., Higashi, H. & Nishi, S. Characterization and ionic basis of GABA-induced depolarizations recorded in vitro from cat primary afferent neurones. J. Physiol. (Lond.) 275, 263-282 (1978).
98. Akaike, N., Inomata, N. & Yakushiji, T. Differential effects of extra- and intracellular anions on GABA-activated currents in bullfrog sensory neurons. J. Neurophysiol. 62, 1388-1399 (1989).
99. Bormann, J., Hamill, O. P. & Sakmann, B. Mechanism of anion permeation through channels gated by glycine and γ-aminobutyric acid in mouse cultured spinal neurones. J. Physiol. (Lond.) 385, 243-286 (1987).
100. A receptors containing the α1 subunit.
101. Crestani, F., Martin, J. R., Möhler, H. & Rudolph, U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol. 131, 1251-1256 (2000)
102. A receptors in hippocampal neurons. Mol. Pharmacol. 59, 814-824 (2001).
103. A receptor subtype-specific modulation of the synchrony and duration of thalamic oscillations. J. Neurosci. 23, 3649-3657 (2003).
104. A receptor channels. Annu. Rev. Neurosci. 17, 569-602 (1994).
105. Rho, J. M., Donevan, S. D. & Rogawski, M. A. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J. Pharmacol. Exp. Ther. 280, 1383-1391 (1997).
106. White, H. S., Brown, S. D., Woodhead, J. H., Skeen, G. A. & Wolf, H. H. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 28, 167-179 (1997).
107. A receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia 41 (Suppl. 1), S25-29 (2000).
108. De Biase, D., Barra, D. Bossa, F., Pucci, P. & John, R. A. Chemistry of the inactivation of 4-aminobutyrate aminotransferase by the antiepileptic drug vigabatrin. J. Biol. Chem. 266, 20056-20061 (1991).
109. Löscher, W. & Horstermann, D. Differential effects of vigabatrin, γ-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedeberg's Arch. Pharmacol. 349, 270-278 (1994).
110. Jackson, M. F., Esplin, B. & Čapek, R. Reversal of the activity-dependent suppression of GABA-mediated inhibition in hippocampal slices from γ-vinyl GABA (vigabatrin)-pretreated rats. Neuropharmacology 39, 65-74 (2000).
111. Overstreet, L. S. & Westbrook, G. L. Paradoxical reduction of synaptic inhibition by vigabatrin. J. Neurophysiol. 86, 596-603 (2001).
112. Wu, Y., Wang, W. & Richerson, G. B. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J. Neurophysiol. 89, 2021-2034 (2003).
113. Richerson, G. B. & Wu, Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J. Neurophysiol. 90, 1363-1374 (2003).
114. Löscher, W. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. J. Neurochem. 34, 1603-1608 (1980).
115. B(1). Neuron 31, 47-58 (2001).
116. Sarup, A., Larsson, O. M. & Schousboe, A. GABA transporters and GABA-transaminase as drug targets. Curr. Drug Target CNS Neurol. Disord. 2, 269-277 (2003).
117. Suzdak, P. D. & Jansen, J. A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36, 612-626 (1995).
118. Thompson, S. M. & Gahwiler, B. H. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J. Neurophysiol. 67, 1698-1701 (1992). Recordings from CA3 hippocampal pyramidal cells demonstrate that tiagabine greatly prolongs the duration of monasynaptic inhibitory synaptic potentials and can also inhibit epileptiform bursting.
119. Engel, D. et al. Laminar difference in GABA uptake and GAT-1 expression in rat CA1. J. Physiol. (Lond.) 512, 643-649 (1998).
120. Jackson, M. F., Esplin, B. & Čapek, R. Activity-dependent enhancement of hyperpolarizing and depolarizing γ-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine. Epilepsy Res. 37, 25-36 (1999).
121. Dingledine, R., Borges, K., Bowie, D. & Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61 (1999).
122. Löscher, W. & Rogawski, M. in Ionotropic Glutamate Receptors as Therapeutic Targets (eds Lodge, D., Danysz, W. & Parsons, C. G.) 91-132 (F. P. Graham, Johnson City, Tennessee, 2002).
123. Rogawski, M. A. et al. GluR5 kainate receptors, seizures, and the amygdala. Ann. NY Acad. Sci. 985, 150-162 (2003).
124. Sheth, R. D. & Gidal, B. E. Refractory status epilepticus: response to ketamine. Neurology 51, 1765-1766 (1998).
125. Boyd, S. G. & Dan, B. Cortical sensitivity in refractory status epilepticus. Clin. Neurophysiol. 111 (Suppl. 1), S156-164 (2000).
126. Mewasingh, L. D. et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure 12, 483-489 (2003).
127. Subramaniam, S. et al. Felbamate block of the N-methyl-D-aspartate receptor. J. Pharmacol. Exp. Ther. 273, 878-886 (1995).
128. Kuo, C. C., Lin, B. J., Chang, H. R. & Hsieh, C. P. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol. Pharmacol. 65, 370-380 (2004).
129. Kleckner, N. W., Glazewski, J. C., Chen, C. C. & Moscrip, T. D. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J. Pharmacol. Exp. Ther. 289, 886-894 (1999).
130. Harty, T. P. & Rogawski, M. A. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 39, 47-55 (2000).
131. Bleakman, D. Kainate receptor pharmacology and physiology. Cell. Mol. Life. Sci. 56, 558-566 (1999).
132. Lerma, J., Paternain, A. V., Rodriguez-Moreno, A. & López-Garcia, J. C. Molecular physiology of kainate receptors. Physiol. Rev. 81, 971-998 (2001).
133. K5-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nature Neurosci. 5, 796-804 (2002).
134. Gryder, D. S. & Rogawski, M. A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 23, 7069-7074 (2003). A demonstration that topiramate inhibits AMPA and kainate receptor mediated synaptic excitation, but is more potent and effective against the kainate receptor-mediated component.
135. Kaminski, R. M., Banerjee, M. & Rogawski, M. A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46, 1097-1104 (2004).
136. Löscher, W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and models with spontaneous recurrent seizures. Epilepsy Res. 50,105-123 (2002).
137. White, H. S. Animal models of epileptogenesis. Neurology 59 (Suppl. 5), S7-14 (2002).
138. Lynch, B. A. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA (in the press).
139. Scheffer, I. E. & Berkovic, S. F. The genetics of human epilepsy. Trends Pharmacol. Sci. 24, 428-433 (2003).
140. Escayg, A. et al. Coding and noncoding variation of the human calcium-channel β4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am. J. Hum. Genet. 66, 1531-1539 (2000).
141. Jouvenceau A. et al. Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 358, 801-807 (2001).
142. Holtmann, M., Opp, J., Tokarzewski, M. & Kom-Merker, E. Human epilepsy, episodic ataxia type 2, and migraine. Lancet 359, 170-171 (2002).
143. Chioza, B. et al. Haplotype and linkage disequilibrium analysis to characterise a region in the calcium channel gene CACNA1A associated with idiopathic generalised epilepsy. Eur. J. Hum. Genet. 10, 857-864 (2002).
144. 1B calcium channel gene CACNA1A and idiopathic generalized epilepsy. Neurology 56, 1245-1246 (2001).